Currently, there are 99.89M common shares owned by the public and among those 59.67M shares have been available to trade.
The company’s stock has a 5-day price change of 0.40% and 48.24% over the past three months. TRVI shares are trading 53.28% year to date (YTD), with the 12-month market performance up to 148.62% higher. It has a 12-month low price of $2.30 and touched a high of $7.39 over the same period. TRVI has an average intraday trading volume of 2.32 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.67%, 0.31%, and 46.39% respectively.
Institutional ownership of Trevi Therapeutics Inc (NASDAQ: TRVI) shares accounts for 51.47% of the company’s 99.89M shares outstanding.
It has a market capitalization of $642.52M and a beta (3y monthly) value of 0.60. The earnings-per-share (ttm) stands at -$0.45. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.47% over the week and 2.79% over the month.
Analysts forecast that Trevi Therapeutics Inc (TRVI) will achieve an EPS of -0.1 for the current quarter, -0.11 for the next quarter and -0.5 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.12 while analysts give the company a high EPS estimate of -0.12. Comparatively, EPS for the current quarter was -0.12 a year ago. Earnings per share for the fiscal year are expected to increase by 6.82%, and -27.22% over the next financial year. EPS should shrink at an annualized rate of -13.45% over the next five years, compared to 27.09% over the past 5-year period.
Looking at the support for the TRVI, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on May 28, 2025, with the firm’s price target at $21. Raymond James coverage for the Trevi Therapeutics Inc (TRVI) stock in a research note released on March 10, 2025 offered a Strong Buy rating with a price target of $29. Needham was of a view on March 10, 2025 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on December 12, 2024, issuing a price target of $6- $7.50. Leerink Partners on their part issued Outperform rating on September 09, 2024.
